Thursday, 15 October 2026European Markets

BELIEVE Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with believe (blv.pa) rising 18.39% to €14.68 on tuesday while cac 40 slid 0.84% to €7,625.31.

believe's last close was €12.40, 2.82% below its 52-week high of €12.76.

about believe

believe s.a. provides music distribution and marketing services for artists and labels worldwide. the company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. it also provides brand partnership, video, synchronization, music publishing and additional services. believe s.a. was incorporated in 2005 and is headquartered in paris, france.

earnings per share

as for profitability, believe has a trailing twelve months eps of €-0.22.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.27%.

sales growth

believe's sales growth is 32.3% for the ongoing quarter and 14.3% for the next.

moving average

believe's worth is way above its 50-day moving average of €10.55 and way higher than its 200-day moving average of €10.24.

more news about believe (blv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com